INVO Fertility (NASDAQ:IVF – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.
Separately, Maxim Group set a $4.00 price target on INVO Fertility in a research note on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $4.00.
Get Our Latest Research Report on IVF
INVO Fertility Trading Down 2.2%
Institutional Investors Weigh In On INVO Fertility
A hedge fund recently bought a new stake in INVO Fertility stock. Citadel Advisors LLC purchased a new position in INVO Fertility, Inc (NASDAQ:IVF – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned 1.19% of INVO Fertility as of its most recent SEC filing. Institutional investors and hedge funds own 12.02% of the company’s stock.
About INVO Fertility
INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.
The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.
See Also
- Five stocks we like better than INVO Fertility
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- What a Former CIA Agent Knows About the Coming Collapse
- Unlocked: Elon Musk’s Next Big IPO
- Elon Musk already made me a “wealthy man”
Receive News & Ratings for INVO Fertility Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INVO Fertility and related companies with MarketBeat.com's FREE daily email newsletter.
